The incidence of lung cancer is the highest among all tumors, and treatment has become an urgent problem to be solved. The Drug-eluting bead-based bronchial arterial chemoembolization (DEB-BACE) combination immunotherapy is a rare neoadjuvant therapy for lung cancer surgery, which can significantly reduce the time it takes for lung cancer patients to undergo surgery.We report a male patient, aged 59-year-old, with Stage-III b squamous cell lung cancer accompanied by hemoptysis underwent surgical resection after DEB-BACE combination immunotherapy treatment 21 days later without obvious adverse events. A pathologic complete response (pCR) was observed postoperatively, and the patient has made a successful recovery. The DEB-BACE combined with immunotherapy might be a new neoadjuvant therapy option for locally advanced non-small cell lung.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668917 | PMC |
http://dx.doi.org/10.2147/IMCRJ.S491862 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!